ALT

Altimmune Inc

Altimmune (NASDAQ:ALT) Stock Price Up 12.2% - Still a Buy...

The consensus price target hints at a 229.3% upside potential for Altimmune (ALT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Geode Capital Management LLC lifted its stake in Altimmune, Inc. (NASDAQ:ALT - Free Report) by 13.4% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission...

Altimmune (NASDAQ:ALT) Shares Down 6.6% - Here's What Happened...

Intech Investment Management LLC lifted its position in shares of Altimmune, Inc. (NASDAQ:ALT - Free Report) by 102.9% during the second quarter, according to the company in its most recent Form 13F...

Shares of Altimmune, Inc. (NASDAQ:ALT - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the ten ratings firms that are presently covering the company, MarketBeat...

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) saw some unusual options trading on Monday. Investors bought 11,978 call options on the company. This is an increase of 103% compared to the typical...

The average of price targets set by Wall Street analysts indicates a potential upside of 250.6% in Altimmune (ALT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Retail traders focused on AI-driven biopsy findings and clearer dose-response exuded increased confidence in pemvidutide’s potential.